The first in-human Phase I study of a BET inhibitor for the treatment of NHL

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of a bromodomain and extra-terminal motif (BET) inhibitor for the treatment of non-Hodgkin lymphoma in a first in-human Phase I study.